Healthcare / Diagnostics & ResearchShenzhen
$8.98
+0.16 (+1.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $31.2M · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-13.3%
↓Gross Margin
43.1%
↓Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.1%
FCF CAGR
—
FCF margin
-0.5%
FCF / Net income
0.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $929.8M · net income $-196.8M · FCF $-5.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $929.8M | $929.8M | $1.08B | $1.15B | $1.37B |
| Net Income | $-196.8M | $-196.8M | $-192.4M | $-427.2M | $-248.9M |
| EBITDA | $-90.5M | $-90.5M | $-68.9M | $-323.1M | $-156.0M |
| EPS | -0.56 | -0.56 | -0.54 | -1.21 | -0.81 |
| Gross Margin | 43.1% | 43.1% | 46.9% | 44.7% | 42.7% |
| Operating Margin | -7.7% | -7.7% | 1.4% | -2.6% | -1.7% |
| Net Margin | -21.2% | -21.2% | -17.8% | -37.1% | -18.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.10 | 0.16 | 0.15 |
| Current Ratio | 2.10 | 2.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.1M | $-5.1M | $31.2M | $55.9M | $-52.1M |
| Returns | |||||
| ROE | -13.3% | -13.3% | -11.5% | -22.9% | -10.8% |
| Valuation | |||||
| P/B | 2.15 | 2.15 | 1.65 | 2.09 | 1.57 |
| Growth & Yield | |||||
| Revenue Growth | -13.8% | -13.8% | -6.4% | -15.8% | — |
| EPS Growth | -2.3% | -2.3% | 55.0% | -49.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.54 → -0.56
Residual
-33.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.